We can’t show the full text here under this license. Use the link below to read it at the source.
Liraglutide Modulates Appetite and Body Weight Through Glucagon-Like Peptide 1 Receptor–Expressing Glutamatergic Neurons
Liraglutide affects appetite and body weight through brain cells responding to GLP-1
AI simplified
Abstract
Mice lacking GLP-1 receptors in glutamatergic neurons experienced a complete loss of liraglutide-induced weight loss and visceral illness.
- GLP-1 receptor agonists are FDA-approved drugs for weight loss.
- The specific neuronal sites where GLP-1R agonists affect appetite and body weight remain unclear.
- Deletion of GLP-1Rs in GABAergic neurons did not affect food intake or body weight in mice.
- Removal of GLP-1Rs from glutamatergic neurons eliminated the weight loss and visceral illness effects of liraglutide.
- This deletion also abolished the neural network activation typically observed after liraglutide administration.
AI simplified